• Profile
Close

Use of low-dose aspirin and mortality after prostate cancer diagnosis: A nationwide cohort study

Annals of Internal Medicine Mar 08, 2019

Skriver C, et al. - In this nationwide cohort study, researchers evaluated the correlation between postdiagnosis use of low-dose aspirin (75-150 mg), defined as ≥ 2 prescriptions filled within 1 year after prostate cancer diagnosis, and prostate cancer mortality. Study participants included men with incident prostate adenocarcinoma between 2000 and 2011. An overall effect of postdiagnosis low-dose aspirin use on prostate cancer mortality was not supported in this analysis. Results for extended exposure periods, however, suggested that low doses of aspirin may be inversely associated with mortality from prostate cancer after 5 years of cancer diagnosis.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay